News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
Amgen (AMGN) Release: FDA Accepts Biologics License Application For Aimovig (erenumab) 7/21/2017
FDA Accepts Biologics License Application For AMG 334 (Erenumab), An Important Regulatory Milestone For Novartis AG (NVS) 7/21/2017
Syros Pharma Publishes Foundational Data Supporting Ongoing Phase II Clinical Trial Of SY-1425 For Genomically Defined AML And MDS Patients 7/21/2017
Merck KGaA (MKGAF.PK) Release: EMA's CHMP Issues Positive Opinion For Avelumab For The Treatment Of Metastatic Merkel Cell Carcinoma 7/21/2017
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer 7/21/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/20/2017
Vertex (VRTX) Gains $8 Billion Overnight as Cystic Fibrosis Combo Drug Wows in Trials 7/20/2017
Ironwood (IRWD)'s Potential Blockbuster Drug Meets Main Goals in Mid-Stage Trial 7/20/2017
Kite Pharma (KITE) Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy 7/20/2017
Trevena (TRVN) To Host 2017 Analyst Day And Announce Results Of ATHENA Open Label Safety Study Of OLINVO 7/20/2017
Intra-Cellular Therapies (ITCI) Presents At The 2017 International College Of Neuro-Psychopharmacology (CINP) Thematic Meeting On Treatment-Resistant Depression 7/20/2017
BiondVax's Universal Flu Vaccine Meets All Endpoints in Phase IIb Study 7/20/2017
Another Alzheimer's Let-Down as FUJIFILM's Candidate Flunks Phase II Test 7/19/2017
Genentech (RHHBY) R&D Exec Reveals Alzheimer's is Still A Priority 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
Data From BioTime (BTX)’s Phase I/IIa Opregen Trial To Be Presented At The 2017 American Academy of Ophthalmology Annual Meeting 7/19/2017
Tiziana Life Sciences Plc Announces Initiation Of A Phase IIa Clinical Trial With Milciclib In Patients With Hepatocellular Carcinoma 7/19/2017
Imago Biosciences Doses First Patients In The Phase IIa Portion Of The Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome 7/19/2017
BriaCell Provides Clinical Update On Its Ongoing Phase I/IIa Clinical Study Of BriaVax In Advanced Breast Cancer 7/19/2017
Evolus Announces FDA Acceptance For Review Of The Biologics License Application For DWP-450 Neuromodulator 7/19/2017
Neurotrope (NTRP) Presents Phase II Data Assessing Bryostatin-1 In Moderate-To-Severe Alzheimer's Patients At AAIC 2017 7/19/2017
Caladrius Biosciences (CLBS) Announces That 50% Of Subjects Have Been Treated In The Phase II Clinical Trial Of CLBS03 For Type 1 Diabetes 7/19/2017
In Alzheimer's, The 'Juggernaut Is Changing Course,' Says TauRx Pharma Chief Exec 7/18/2017
Centrexion Provides Updates And Advancements For Pipeline Of Chronic Pain Treatments 7/18/2017
Aldeyra (ALDX) Announces Last Patient Dosed In Dry Eye Disease Phase IIa Clinical Trial 7/18/2017
Capricor (CAPR) Receives Rare Pediatric Disease Designation From FDA For CAP-1002 For Patients With Duchenne Muscular Dystrophy 7/18/2017
Can-Fite BioPharma (CFBI)’s Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting 7/17/2017
WAVE Life Sciences (WVE) Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 And PRECISION-HD2 In Patients With Huntington’s Disease 7/17/2017
Apexigen Announces First Patient Dosed In Phase Ib/II Clinical Trial Of APX005M In Combination With Opdivo (Nivolumab) In Advanced Solid Tumors 7/17/2017
Proclara Announces Pipeline Progress 7/17/2017
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's AIS-A 20 Million Cell Cohort 7/17/2017
Cancer Prevention Pharma In Collaboration With The NCI And Vanderbilt University Medical Center Initiates Phase II Trial To Evaluate CPP-1X In Patients With High Risk Of Gastric Cancer 7/17/2017
Axsome (AXSM) Initiates Phase II/III Trial Of AXS-05 For Alzheimer’s Disease Agitation 7/17/2017
No Relief For Investors As The FDA Keeps Partial Hold On Radius Health (RDUS)'s Proellex Program 7/17/2017
AXON Neuroscience's Tau Vaccine Has Completed Phase II Enrolment In Alzheimer's 7/17/2017
CymaBay Therapeutics Announces Positive Interim Results From Its Ongoing Low-Dose Phase II Study Of Seladelpar In Patients With Primary Biliary Cholangitis 7/17/2017
RedHill Biopharma (RDHL) Announces Last Patient Visit In BEKINDA Phase II Study For IBS-D 7/17/2017
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II 7/14/2017
Innovation Pharma (Formerly known as Cellceutix) (CTIX) Phase II PoC Trial For Inflammatory Bowel Disease Achieves Induction Of Remission In A Majority Of Patients Treated With Brilacidin 7/14/2017
San Diego's Arena (ARNA) Soars as Phase II Hypertension Trial Data Wows 7/13/2017
Viamet Release: FDA Grants Fast Track Designation To VT-1598 For Treatment Of Valley Fever 7/13/2017
Initiation Of Clinical Trial Collaboration Evaluating Halozyme (HALO)'s PEGPH20 In Combination With Anti-PDL1 Immunotherapy 7/13/2017
Advaxis (ADXS) Lead Immunotherapy Candidate Continues To Build Recognition Among Industry Leaders 7/13/2017
New Experimental Data On Anti-Inflammatory Effects Of ABX464, Abivax (ABVX.PA)'s First-In-Class Drug Candidate To Achieve Functional Cure In HIV-Patients, Published In Nature Scientific Reports 7/13/2017
Actinium (ATNM.OB) To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET 7/13/2017
Publication In Cell Demonstrates Moderna’s Zika Mrna Vaccine Prevents In Utero Transmission Of Zika Virus In Mice, Protects Against Zika-Related Congenital Damage 7/13/2017
CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma 7/13/2017
FDA Grants Orphan Drug Designation To Mallinckrodt (MNK) Development Product For Potential Treatment Of Duchenne Muscular Dystrophy 7/13/2017
FDA Grants Orphan Drug Designation To Allena Pharma’ Investigational Therapy For The Treatment Of Primary Hyperoxaluria 7/13/2017
Viking Therapeutics (VKTX) Completes Enrollment In Phase II Study Of VK5211 In Patients Recovering From Hip Fracture 7/12/2017
Neuraltus Pharmaceuticals, Inc. Announces Completion Of Enrollment In Confirmatory Phase II Study Of NP001 In ALS Patients With Systemic Inflammation 7/12/2017
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's Ais-B 10 Million Cell Cohort 7/12/2017
Camurus And Braeburn Pharma Announce Topline Phase II Results For Long-Acting Buprenorphine In Opioid Dependent Patients With Chronic Pain 7/12/2017
QR Pharma Presents New Data On Posiphen In Down Syndrome At The Alzheimer's Disease International Conference (AAIC 2017 London) 7/12/2017
Vifor Pharma Announces Three Outcomes Trials In Heart Failure And Iron Deficiency 7/12/2017
Dimerix Limited Reports Positive Results From Phase IIa Trial Of DMX-200 In Chronic Kidney Disease 7/12/2017
Why Biogen (BIIB) Spinoff Bioverativ (BIVV)'s Anemia Drug Could Be A Blockbuster 7/11/2017
Savara Release: Positive Interim Results Of Aironite Phase II Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension 7/11/2017
BioMarin (BMRN)'s Investigational Gene Therapy For Hemophilia A At 6e13 Vg/Kg Dose Maintains Average Factor VIII Levels Within Normal Range For Over One Year 7/11/2017
ProMetic Life Sci (PFSCF.PK) Announces Positive Long Term Clinical Data On Ryplazym In Plasminogen Congenital Deficiency And Provides Regulatory Update 7/11/2017
Valerion Therapeutics, LLC Initiates VAL-1221 Dosing In Patients With Pompe Disease 7/11/2017
Oramed (ORMP) Announces End-Of-Phase II Meeting With FDA To Initiate Phase III Program 7/11/2017
Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA For Treatment Of Pemphigus Vulgaris 7/11/2017
Kadmon Announces Interim Phase II Data Of KD025 In Chronic Graft-Versus-Host Disease 7/11/2017
uniQure (QURE) Presents New Clinical Data In Hemophilia B Patients Demonstrating Therapeutic Efficacy Of AAV5 Gene Therapy In The Presence Of Pre-Existing Neutralizing Antibodies 7/11/2017
Neovasc (NVC) Announces Positive IDSMB Review For Phase Iib Clinical Trial Of Ifnalpha Kinoid In Lupus 7/11/2017
Concert Pharma (CNCE) Jumps As The FDA Lifts Clinical Hold On Hair Loss Drug Study 7/10/2017
Massachusetts' Inotek (ITEK) Exploring Strategic Alternatives After Another Glaucoma Trial Failure 7/10/2017
Parkinson’s Disease: Prexton Announces Initiation Of Phase II Clinical Testing 7/10/2017
Ignyta (RXDX) Receives FDA Orphan Drug Designation For Entrectinib For Treatment Of NTRK Fusion-Positive Solid Tumors 7/10/2017
Asterias Biotherapeutics Receives FDA Clearance To Enroll C-4 Patients In SCiStar Study 7/10/2017
FDA Accepts For Priority Review Bristol-Myers Squibb (BMY)’s Application For Sprycel (Dasatinib) In Children With Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia 7/10/2017
Boston Biomedical Announces Orphan Drug Designation By FDA For Investigational WT1 Cancer Peptide Vaccine DSP-7888 In Myelodysplastic Syndrome 7/10/2017
BioLineRx Announces Initiation Of Phase Ib/II Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration 7/10/2017
Inotek (ITEK) Announces Top-Line Results Of Phase II Fixed-Dose Combination Trial Of Trabodenoson And Provides Corporate Update 7/10/2017
Alnylam (ALNY) And Sanofi Genzyme (SNY) Report Positive Results From Ongoing Phase II Open-Label Extension Study With Investigational Rnai Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors 7/10/2017
Published Results From Clinical Trials Demonstrate Therapeutic Potential For Immunomedics (IMMU)’ Sacituzumab Govitecan (IMMU-132) In The Treatment Of Metastatic Solid Cancers 7/10/2017
Immuron Release: NASH Phase II Interim Analysis Reveals Improvement In Liver Enzymes (AST And ALT) With Good Safety And Tolerability 7/10/2017
Spring Bank Pharmaceuticals, Inc. Announces Collaboration With Gilead (GILD) For Hepatitis B (HBV) Phase II Study Exploring Combination Treatment Of SB 9200 And Vemlidy 7/10/2017
Global Blood Therapeutics (GBT) Expands Ongoing Phase IIa HOPE-KIDS 1 Study Into Younger Pediatric Population 7/10/2017
AC Immune SA Provides Seven Updates On Its Pipeline And Technology At The Alzheimer's Association International Conference 7/10/2017
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Bardoxolone Methyl For The Treatment Of Alport Syndrome 7/10/2017
Mark Your Calendars: 7 Biotechs Facing Important Catalysts in July 7/7/2017
Argenx Presents Full Data From ARGX-111 Phase Ib Study In Patients With Advanced Cancers Over-Expressing The MET Protein At Best Of ASCO Asia 2017 (Singapore) 7/7/2017
New Data To Be Presented At Isth Underscore Bioverativ (BIVV)’s Commitment To Advance Hemophilia Care 7/6/2017
TrovaGene (TROV) Engages Leading CRO In AML To Conduct Phase Ib/II Trial Of PCM-075 7/6/2017
Soligenix (SNGX) Release: Dusquetide Technology Platform To Be Presented At The 2017 Drug Discovery And Therapy World Congress 7/6/2017
Actinium (ATNM.OB) To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET 7/6/2017
Prothena (PRTA) Announces Initiation Of Phase II PASADENA Study Of PRX002/RG7935 In Patients With Early Parkinson’s Disease 7/6/2017
3 Biotechs With Bulging Pipelines That Could Also Become Attractive Takeover Targets 7/6/2017
Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug 7/6/2017
Omeros (OMER): Next Big Thing In Biotech 7/5/2017
PTC Therapeutics (PTCT) Release: Preliminary Phase II Data From Spinal Muscular Atrophy Program Presented At CureSMA Conference 7/5/2017
RDD Pharma Receives Orphan Designation For RDD-0315 In Spinal Cord Injury Patients In The European Union 7/5/2017
Galapagos (GLPG.BR) Release: New Phase II Study With Filgotinib In Non-Infectious Uveitis 7/5/2017
Cytokinetics (CYTK) Announces Baseline Data From First Cohort Of Phase II Clinical Trial Of CK-2127107 In Patients With SMA 7/5/2017
BeiGene (BGNE) Initiates Pivotal Trial Of PD-1 Antibody BGB-A317 In China In Patients With Urothelial Cancer 7/5/2017
NOXXON Pharma AG Announces First Patients Treated In Phase I/II Clinical Trial Of Nox-A12 Combined With Keytruda In Metastatic Pancreatic And Colorectal Cancer 7/5/2017
Bionomics Limited (BNO.AX): A Company With Deals On The Horizon 7/5/2017
Mixed Phase II Osteoarthritis Data Sends Cara Therapeutics (CARA)' Stock Plunging 6/30/2017
Boston Biomedical Presents Data For Investigational Cancer Stemness Inhibitor Napabucasin In Metastatic Colorectal And Pancreatic Cancer At ESMO GI 2017 6/30/2017
Windtree Therapeutics (WINT) Announces Top-Line Results From AEROSURF Phase IIb Clinical Trial For The Treatment Of Respiratory Distress Syndrome (RDS) In Premature Infants 6/30/2017
Neurotrope (NTRP) To Present Bryostatin Phase 2 Data In An Oral Presentation At AAIC 2017 Meeting 6/30/2017
GOP Congressman Lost $16.7 Million in Single Day on This Tanking Biotech Stock 6/29/2017
A Look at the Deaths That Plagued Juno (JUNO) and Kite Pharma (KITE)'s CAR-T Trials 6/29/2017
Stealth Biotherapeutics Presents Phase II Data From MMPOWER-2 Continuation Trial Supporting Phase III Development Of Elamipretide In Primary Mitochondrial Myopathy 6/29/2017
Aclaris (ACRS) Initiates Phase IIb Clinical Trials Of A-101 For Topical Treatment Of Common Warts 6/29/2017
ObsEva (OBSV) Announces Presentations Related To Its Assisted Reproductive Technology (ART) And Pre-Term Labor (PTL) Development Programs At ESHRE 2017 Annual Meeting 6/29/2017
Can Merck & Co. (MRK) And Novartis AG (NVS)'s Surprise Heart Drug Success Translate To Blockbuster Sales? 6/29/2017
Aerpio Announces Initiation Of Patient Dosing In The TIME-2b Study, A Phase IIb Clinical Trial Of Lead Candidate AKB-9778 In Patients With Diabetic Retinopathy 6/29/2017
GenKyoTex S.A. Initiates Patient Enrollment Into Phase II Trial Of GKT831 In Primary Biliary Cholangitis 6/29/2017
Aduro Biotech (ADRO) Announces First Patient Dosed In Phase II Clinical Trial Of CRS-207 In Combination With KEYTRUDA® (Pembrolizumab) For The Treatment Of Patients With Previously Treated Malignant Pleural Mesothelioma 6/29/2017
Gemphire Announces Top-Line Data from COBALT-1 Phase IIb Clinical Trial in HoFH Patients 6/29/2017
Halozyme (HALO) Phase II Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium 6/28/2017
Teva (TEVA) And Xenon Pharma Announce Phase II Study Of Topical TV-45070 In Patients With Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint 6/27/2017
TP Therapeutics Announces FDA Orphan Drug Designation Granted To TPX-0005 For Treatment Of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, Or NTRK Oncogenic Rearrangements 6/27/2017
Ra Pharma (RARX) Announces Initial Data From Phase II Clinical Trial Of RA101495 In PNH 6/27/2017
Alnylam (ALNY) And Sanofi Genzyme (SNY) To Present New Clinical Trial Results At The International Society Of Thrombosis And Haemostasis (ISTH) Congress 6/27/2017
Araclon Biotech Initiates Phase II Clinical Trials Of Its Alzheimer's Vaccine 6/27/2017
TrovaGene (TROV) Announces Submission Of Investigational New Drug Application To Initiate Phase Ib/II Clinical Trial Of PCM-075 For Acute Myeloid Leukemia 6/27/2017
TapImmune (TPIV) Reaches 50% Patient Enrollment Benchmark In Phase II Study Of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer 6/27/2017
Bavarian Nordic (BAVA.CO) Announces Positive Data From Ongoing Phase II Study Investigating A Universal RSV Vaccine 6/27/2017
Xenon Pharma To Host Conference Call And Webcast Today At 9:00 A.M. Eastern Time To Discuss Topline Results From TV-45070 Phase IIb Clinical Trial In PHN 6/27/2017
Sound Pharmaceuticals, Inc. Completes Enrollment On Meniere's Disease Clinical Trial 6/27/2017
Results Of NeuroDerm (NDRM)’s ND0612H Phase II Trial Presented In Oral Session At The 3rd Congress Of The European Academy Of Neurology 6/27/2017
Marinus Pharma (MRNS) Launches The Ganaxolone Clinical Program In Patients With Postpartum Depression 6/27/2017
Will AbbVie (ABBV) Outsmart Biosimilars, And Can Clovis Oncology (CLVS) Win The PARP Race? 6/27/2017
FDA Calls Cara Therapeutics (CARA)' Kidney Disease Drug a Breakthrough, Stock Soars 6/26/2017
Verona Pharma (VRP.L) Receives Regulatory Approval To Commence Phase IIb Clinical Trial Of RPL554 For COPD Maintenance Treatment In Five Countries Across Europe 6/26/2017
Verastem (VSTM) Reports Phase II Long-Term Follow-Up Data For Duvelisib In Patients With Double-Refractory Follicular Lymphoma And Small Lymphocytic Lymphoma At The 22nd Congress Of The European Hematology Association 6/26/2017
Semnur Announces Successful Phase I/II Trial In Patients With Radicular Pain For Its Lead Product, SP-102 6/26/2017
European Hematology Association: Clinical And Biologic Covariates Of Outcomes In ZUMA-1: A Pivotal Trial Of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) In Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL) 6/26/2017
European Hematology Association: Global Trial Of The Efficacy And Safety Of CTL019 In Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: An Interim Analysis Of The JULIET Study 6/26/2017
European Hematology Association: Multicenter Open-Label Phase 2 Study Of Ibrutinib In Chronic Graft Versus Host Disease (cGVHD) After Failure Of Corticosteroids 6/26/2017
NewVac Presented Results Of Quisinostat's Phase II Clinical Trial At ASCO 2017 6/26/2017
Innovation Pharma (Formerly known as Cellceutix) (CTIX) Completes Treatments In Phase II PoC Trial For Induction Of Remission In Inflammatory Bowel Disease; Topline Results With Endoscopic Response To Be Presented July 13, 2017 6/26/2017
Advaxis (ADXS)’ Axalimogene Filolisbac Data Selected For Poster Presentation At ESGO 2017 6/26/2017
Xenetic Biosciences Commences Patient Enrollment In Phase II Study Evaluating XBIO-101 In Conjunction With Progestin Therapy For The Treatment Of Endometrial Cancer 6/26/2017
Matinas BioPharma (MTNB) Tanks As Lead Drug Fails To Match Standard-Of-Care Treatment In Phase II Infection Trial 6/26/2017
SoCal's Neothetics (NEOT) Craters As Fat-Reduction Drug Flunks Phase II Study 6/26/2017
Agios (AGIO) Announces Updated Data From Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential As The First Disease-Modifying Treatment For Patients With Pyruvate Kinase Deficiency 6/26/2017
TG Therapeutics (TGTX) Recaps Data From Triple Combination Therapy Trials At The 22nd European Hematology Association Annual Congress 6/26/2017
TG Therapeutics (TGTX) Recaps Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The 3rd Congress Of The European Academy Of Neurology 6/26/2017
Mithra Pharmaceuticals Estelle Phase IIb Results On Well-Being And Body Weight Published In Leading Peer-Reviewed Journal 6/26/2017
Amgen (AMGN) Goes on the Defensive When Critics Call Its Pipeline a Dud 6/23/2017
Kadmon To Present Interim Data On KD025 In Chronic Graft-Versus-Host Disease (cGVHD) At R&D Day 6/23/2017
Global Blood Therapeutics (GBT) Announces New Data Supporting Ongoing Clinical Development Of GBT440 In Adolescents With Sickle Cell Disease 6/23/2017
Braeburn Pharma Release: Phase II Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder 6/23/2017
bluebird bio (BLUE) Presents New Data From HGB-205 Study Of LentiGlobin Drug Product In Patients With Transfusion-Dependent ?-Thalassemia (TDT) And Severe Sickle Cell Disease (SCD) At European Hematology Association Annual Meeting 6/23/2017
Takeda (TKPYY) Presents Data From Phase I/II Studies For NINLARO (Ixazomib) In Newly Diagnosed Multiple Myeloma Patients And In The Maintenance Setting 6/23/2017
Syros Pharma Presents Data At EHA Supporting Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients 6/23/2017
The Lancet Oncology Publishes Anti-Leukemic Activity And Safety Data For Gilteritinib In Relapsed/Refractory Acute Myeloid Leukemia 6/23/2017
Bellicum (BLCM) Announces Clinical Data On BPX-501 At Presidential Symposium Of The 22nd Congress Of The European Hematology Association 6/23/2017
Bellicum (BLCM) Reports Clinical Results Of BPX-501 In Pediatric Leukemias At The 22nd Congress Of The European Hematology Association 6/23/2017
Stemline (STML) Presents SL-401 Updated Stage 1 And 2 Data From Ongoing Pivotal Trial In BPDCN And Safety Experience Across Multiple Indications, Today At European Hematology Association 6/23/2017
Novartis AG (NVS) Pivotal CTL019 6-Month Follow-Up Data Show Durable Remission Rates In Children, Young Adults With R/R B-Cell ALL 6/23/2017
Novartis AG (NVS) Data Shows Half Of Eligible Ph+ CML-CP Patients Remain In Treatment-Free Remission Nearly Two Years After Stopping Tasigna 6/23/2017
Karyopharm (KPTI) Reports Updated Phase IIb SADAL Data For Selinexor In Diffuse Large B-Cell Lymphoma At The 2017 European Hematology Association Annual Meeting 6/23/2017
Why This Small Biotech With A Single Drug In Human Trials Might Be A Big Winner 6/22/2017
Ionis Pharma (IONS) Release: Enrollment In Phase I/IIa Study Of IONIS-HTT Rx In Patients With Huntington's Disease Completed And Open-Label Extension Study To Open In 2H 2017 6/22/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China 6/22/2017
Opko Health (OPK) Announces KDIGO Clinical Practice Guideline Update On CKD-MBD 6/22/2017
Otonomy (OTIC) Announces Successful End-Of-Phase II Review By FDA For OTIPRIO In Acute Otitis Media With Tympanostomy Tubes 6/22/2017
FibroGen (FGEN) Granted Orphan Drug Designation For Pamrevlumab In The Treatment Of Pancreatic Cancer 6/22/2017
Zealand Pharma  (ZEAL.CO) Release: Phase IIa Trial Results Support Development Of Dasiglucagon In The ILet Pump System For Type 1 Diabetes 6/22/2017
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Omaveloxolone For The Treatment Of Friedreich’s Ataxia 6/22/2017
Herantis Pharma's Lymfactin Study Advances To Last Patient Cohort, Company Announces Initial Plans For Continued Development 6/22/2017
BioPharmX To Present Phase IIb Clinical Trial Acne Data At Alabama Dermatology Society Summer Symposium 6/22/2017
RXi Pharma (RXII) Announces Completion Of Enrollment Of Phase I/II Clinical Trial With RXI-109 For Retinal Scarring 6/21/2017
InDex Pharmaceuticals AB Enrolls First Patient In The Phase IIb Study CONDUCT With Cobitolimod 6/21/2017
Vanda (VNDA): Several Catalysts Coming Up 6/21/2017
Tolero Pharmaceuticals To Expand Enrollment Of Phase II Study Of Alvocidib In MCL-1-Dependent AML Into Europe 6/21/2017
Epizyme (EPZM) Announces Tazemetostat Granted Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma 6/21/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients 6/21/2017
ErgoMed Release: PeproStat Phase IIb Study Passes Recruitment Mid-Point Ahead Of Schedule 6/21/2017
OncoArendi Therapeutics SA Announces Selection Of Its Second Clinical Development Candidate: OATD-02 For The Treatment Of Multiple Cancers 6/21/2017
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/20/2017
Neurotech Announces Positive Phase II Results In NT-501 (CNTF) For Macular Telangiectasia 6/20/2017
ARCA biopharma Announces Database Lock For GENETIC-AF Phase IIB Interim Efficacy Analysis – DSMB Recommendation Anticipated In August 2017 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Neovacs Announces The Completion Of Patient Enrollment In Phase IIb Clinical Study Of IFNalpha Kinoid In Lupus 6/20/2017
Immunicum Announces Publication In Journal For Immunotherapy Of Cancer Of Results Overview From Ilixadencel's First Clinical Study In Metastatic Renal Cell Carcinoma 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Enzychem Lifesciences, Corp Announces Initiation Of Global Phase II Trial Of EC-18 In Patients With Chemotherapy Induced Neutropenia(CIN) 6/20/2017
New Data Reveals This New York Biotech's Pipeline Could be a Game Changer 6/19/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines 6/19/2017
GeNeuro Announces First Patient Treated In Phase IIa Study With Gnbac1 In Type 1 Diabetes 6/19/2017
Celgene (CELG) Release: Updated Data From Phase IIb MAGNIFY Study Of REVLIMID (Lenalidomide) And Rituximab Combination (R2) Show Clinical Activity And Responses In Relapsed/Refractory Follicular And Marginal Zone Lymphoma 6/19/2017
Soligenix (SNGX) Release: Complete Efficacy And Long-Term Follow-Up Safety Results From SGX942 Phase II Oral Mucositis Clinical Trial To Be Presented At The 2017 Multinational Association For Supportive Care In Cancer Conference 6/19/2017
Aldeyra (ALDX) To Present Novel Data On The Anti-Inflammatory Mechanism And Activity Of ADX-102 At The World Congress On Inflammation 2017 Annual Meeting 6/19/2017
Merrimack (MACK) Announces Completion Of Enrollment In Phase II CARRIE Study Of MM-141; Data Expected In First Half Of 2018 6/19/2017
Boston Therapeutics Reports Data From The POC Asia Trial At The American Diabetes Association’s 77th Scientific Sessions 6/19/2017
Axovant (AXON) Release: FDA Grants Fast Track Designation To Axovant's Nelotanserin For Visual Hallucinations In Dementia With Lewy Bodies 6/19/2017
Genexine Co. Ltd. Receives Approval To Initiate Phase Ib/II Trial Of GX-188E, HPV Therapeutic DNA Vaccine, In Combination With KEYTRUDA (Pembrolizumab), For The Treatment Of HPV-Induced Cervical Cancer 6/19/2017
BioTime (BTX) Expands & Advances Ophthalmology Portfolio 6/19/2017
Exelixis (EXEL) Announces Independent Radiology Committee Review Confirms Results From CABOSUN, The Phase II Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/19/2017
Ammonett Pharma Granted Orphan Drug Designation From The U.S. FDA For Ibutamoren Mesylate (MK-0677) For Treatment Of Growth Hormone Deficiency 6/19/2017
Zealand Pharma  (ZEAL.CO) Release: Glepaglutide Meets Primary Endpoint In Phase II Trial In Patients With Short Bowel Syndrome 6/19/2017
VBL Therapeutics (VBLX) Provides Update On Long-Term Survival In Phase II Trials Of Patients With Multiple Tumor Types 6/19/2017
Aurinia (AUPH) Release: Voclosporin Remission Data From The Phase IIb AURA-LV Study Highlighted At EULAR 2017 6/16/2017